197 related articles for article (PubMed ID: 18767952)
1. Development of multi-epitope vaccines targeting wild-type sequence p53 peptides.
DeLeo AB; Whiteside TL
Expert Rev Vaccines; 2008 Sep; 7(7):1031-40. PubMed ID: 18767952
[TBL] [Abstract][Full Text] [Related]
2. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.
Sakakura K; Chikamatsu K; Furuya N; Appella E; Whiteside TL; Deleo AB
Clin Immunol; 2007 Oct; 125(1):43-51. PubMed ID: 17631051
[TBL] [Abstract][Full Text] [Related]
3. p53 as an immunotherapeutic target in head and neck cancer.
Hoffmann TK; Bier H; Donnenberg AD; Whiteside TL; De Leo AB
Adv Otorhinolaryngol; 2005; 62():151-60. PubMed ID: 15608425
[TBL] [Abstract][Full Text] [Related]
4. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.
Cicinnati VR; Zhang X; Yu Z; Ferencik S; Schmitz KJ; Dworacki G; Kaczmarek E; Oldhafer K; Frilling A; Baba HA; Schmid KW; Grosse-Wilde H; Broelsch CE; DeLeo AB; Gerken G; Beckebaum S
Int J Cancer; 2006 Dec; 119(12):2851-60. PubMed ID: 16998881
[TBL] [Abstract][Full Text] [Related]
5. Impact of p53-based immunization on primary chemically-induced tumors.
Cicinnati VR; Dworacki G; Albers A; Beckebaum S; Tüting T; Kaczmarek E; DeLeo AB
Int J Cancer; 2005 Mar; 113(6):961-70. PubMed ID: 15514940
[TBL] [Abstract][Full Text] [Related]
6. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.
Kuball J; Schuler M; Antunes Ferreira E; Herr W; Neumann M; Obenauer-Kutner L; Westreich L; Huber C; Wölfel T; Theobald M
Gene Ther; 2002 Jul; 9(13):833-43. PubMed ID: 12080377
[TBL] [Abstract][Full Text] [Related]
7. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.
Espenschied J; Lamont J; Longmate J; Pendas S; Wang Z; Diamond DJ; Ellenhorn JD
J Immunol; 2003 Mar; 170(6):3401-7. PubMed ID: 12626601
[TBL] [Abstract][Full Text] [Related]
8. Cellular Mucins: Targets for Immunotherapy.
Apostolopoulos V; McKenzie IFC
Crit Rev Immunol; 2017; 37(2-6):421-437. PubMed ID: 29773028
[TBL] [Abstract][Full Text] [Related]
9. p53-based immunotherapy of cancer. Approaches ro reversing unresponsiveness to T lymphocytes and preventing tumor escape.
De Leo AB
Adv Otorhinolaryngol; 2005; 62():134-50. PubMed ID: 15608424
[TBL] [Abstract][Full Text] [Related]
10. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.
Hoffmann TK; Nakano K; Elder EM; Dworacki G; Finkelstein SD; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2000 Nov; 165(10):5938-44. PubMed ID: 11067956
[TBL] [Abstract][Full Text] [Related]
11. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
[TBL] [Abstract][Full Text] [Related]
12. Generation of cancer vaccine immunogens derived from major histocompatibility complex (MHC) class I molecules using variable epitope libraries.
Servín-Blanco R; Chávaro-Ortiz RM; Zamora-Alvarado R; Martínez-Cortes F; Gevorkian G; Manoutcharian K
Immunol Lett; 2018 Dec; 204():47-54. PubMed ID: 30339819
[TBL] [Abstract][Full Text] [Related]
13. Wildtype p53-specific antibody and T-cell responses in cancer patients.
Pedersen AE; Stryhn A; Justesen S; Harndahl M; Rasmussen S; Donskov F; Claesson MH; Pedersen JW; Wandall HH; Svane IM; Buus S
J Immunother; 2011; 34(9):629-40. PubMed ID: 21989411
[TBL] [Abstract][Full Text] [Related]
14. Targeting p53 as a general tumor antigen.
Theobald M; Biggs J; Dittmer D; Levine AJ; Sherman LA
Proc Natl Acad Sci U S A; 1995 Dec; 92(26):11993-7. PubMed ID: 8618830
[TBL] [Abstract][Full Text] [Related]
15. p53-based immunotherapy of cancer.
DeLeo AB
Crit Rev Immunol; 1998; 18(1-2):29-35. PubMed ID: 9419445
[TBL] [Abstract][Full Text] [Related]
16. Synthetic and immunological studies on the OCT4 immunodominant motif antigen-based anti-cancer vaccine.
Chen T; Liu K; Xu J; Zhan T; Liu M; Li L; Yang Z; Yuan S; Zou W; Lin G; Carson DA; Wu CCN; Wang X
Cancer Biol Med; 2020 Feb; 17(1):132-141. PubMed ID: 32296581
[No Abstract] [Full Text] [Related]
17. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope.
Hoffmann TK; Loftus DJ; Nakano K; Maeurer MJ; Chikamatsu K; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2002 Feb; 168(3):1338-47. PubMed ID: 11801674
[TBL] [Abstract][Full Text] [Related]
18. An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53.
Blaszczyk-Thurin M; Ertl IO; Ertl HC
Scand J Immunol; 2002 Oct; 56(4):361-75. PubMed ID: 12234257
[TBL] [Abstract][Full Text] [Related]
19. Myeloid dendritic cells loaded with dendritic tandem multiple antigenic telomerase reverse transcriptase (hTERT) epitope peptides: a potentially promising tumor vaccine.
Niu BL; Du HM; Shen HP; Lian ZR; Li JZ; Lai X; Wei SD; Zou LQ; Gong JP
Vaccine; 2012 May; 30(23):3395-404. PubMed ID: 22480929
[TBL] [Abstract][Full Text] [Related]
20. In silico analyses of Wilms׳ tumor protein to designing a novel multi-epitope DNA vaccine against cancer.
Khalili S; Rahbar MR; Dezfulian MH; Jahangiri A
J Theor Biol; 2015 Aug; 379():66-78. PubMed ID: 25936349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
